Two Minutes to Decide If You Need Wegovy

By 2026, LifeMD was offering the new Wegovy oral pill starting at $149 per month, making it one of the most accessible on-ramps to GLP-1 therapy anywhere. Novo Nordisk now lists eight telehealth partners for the Wegovy pill, with LifeMD positioned as a preferred virtual hub.

This isn't a passive endorsement. Novo Nordisk essentially built a direct-to-consumer distribution network with telehealth companies as the storefront. When one of those storefronts allegedly cuts corners on safety, the manufacturer's fingerprints are on the building.

A Pattern, Not an Anomaly

The LifeMD allegations don't exist in isolation. They sit inside a growing pile of regulatory actions and investigations that suggest the telehealth-GLP-1 gold rush has a systemic safety problem.

The FDA has issued 30 warning letters to telehealth companies for false or misleading claims about GLP-1 products. The FTC finalized an enforcement order against NextMed, another telehealth provider, for deceptive weight-loss advertising tied to GLP-1 demand, including fake testimonials and hidden billing practices.

And Novo Nordisk itself has been under the microscope. In March 2026, the FDA hit the company with a warning letter for "serious violations" of post-marketing safety reporting requirements. Inspectors found that Novo Nordisk failed to properly collect, assess, and report suspected side effects across its product portfolio, including cases involving strokes, suicidal ideation, and deaths. The FDA called it evidence of "systemic failures."

Separately, in September 2025, the FDA's advertising division cited Novo Nordisk for a promotional video that created a "misleading impression regarding the safety" of Wegovy, Ozempic, and Victoza. The video omitted a boxed warning for thyroid tumors and skipped mentions of pancreatitis, gallbladder disease, and kidney injury. Clinical trial data showed approximately 62% of adult Wegovy patients experienced gastrointestinal side effects, compared to about 42% on placebo. That's a pretty important detail to leave out of your marketing.

The Ethics Problem Nobody Wants to Talk About

A U.S. Senate investigation into direct-to-consumer telehealth platforms found that these "novel relationships" between manufacturers and telehealth companies appear "intended to steer patients toward particular medications," raising serious conflict-of-interest concerns.

When a manufacturer runs a platform that helps patients obtain its own drug, the structure raises obvious conflict-of-interest questions. Critics have also raised concerns about consent processes at telehealth companies, arguing that "the consent is not adequate" and there's "no probing to see if patients understood anything."

The concern isn't theoretical. When a pharma company partners with a telehealth firm to sell its drug, and that telehealth firm allegedly pushes two-minute consultations to maximize prescriptions, you've created a system where the incentives all point in one direction: more prescriptions, more revenue, less friction. Patient safety becomes the thing that slows you down.

It's like hiring a personal shopper and then being surprised when they always recommend the most expensive item. The structure of the relationship creates the outcome.

Fragmented Care, Compounded Risk

There's another layer to this that clinicians find genuinely alarming. When patients get GLP-1 prescriptions from a single-purpose telehealth app but see separate doctors for everything else, nobody has the full picture. Drug interactions get missed. Side effects go unreported. The patient becomes the messenger between providers who don't talk to each other.

Many patients, as experts point out, don't know all their medication names or potential side effects. Asking them to coordinate their own care across fragmented platforms isn't patient empowerment; it's a liability.

Critics have noted that some telehealth programs impose burdensome compliance requirements and can remove medication access if patients don't meet them, even when there's no clinical basis for doing so. These models often prioritize employer needs over patient needs.

What Happens Next

Novo Nordisk responded to its FDA warning letter by saying it "takes post-marketing adverse drug experience reporting requirements seriously" and intends to address the issues. The company hasn't publicly responded to the STAT investigation.

But the regulatory walls are closing in from multiple directions. FDA, FTC, DOJ, and Congress are all now actively scrutinizing how telehealth companies prescribe and sell GLP-1 drugs. The question is whether the industry can self-correct before regulators force the issue.

The GLP-1 market is expected to be worth hundreds of billions. Telehealth made these drugs accessible to millions of people who couldn't get them through traditional channels. That's genuinely valuable. But accessibility without adequate safety isn't healthcare; it's commerce wearing a lab coat. And two minutes per patient isn't medicine. It's a transaction.

Abbott's Hackers Claim 30 Million Records. Abbott Says Everything's Fine.

Abbott disclosed two cyberattacks in July 2026 while posting a strong $12.6 billion quarter. Hackers claim they stole 30 million records, including Social Security numbers and doctor-patient notes. Wall Street barely blinked, but should it have?